Response to first-line pembrolizumab in metastatic KRAS -mutated non-small-cell lung cancer.
Sabrina RossiArianna PagliaroGiovanna FinocchiaroArianna MarinelloLaura GiordanoEmilio BriaAlessio StefaniAntonio VitaleLuca ToschiEttore D'ArgentoArmando SantoroPublished in: Future oncology (London, England) (2024)
Aims: This retrospective study aims to identify a possible predictive role of KRAS mutations in non-small-cell lung cancer in response to first-line pembrolizumab, either as monotherapy or combined with chemotherapy. Methods: Patients received pembrolizumab alone (n = 213) or associated with chemotherapy (n = 81). Results: A mutation in the KRAS gene was detected in 27% of patients. In patients on pembrolizumab alone, median progression-free survival in KRAS -mutated cases was longer than in wild-type cases (11.3 vs 4.4 months; p = 0.019), whereas median overall survival did not reach statistical significance (22.1 vs 12.5 months; p = 0.119). Patients receiving chemo-immunotherapy with KRAS -positive tumors had a similar progression-free survival (9.7 vs 7.3 months; p = 0.435); overall survival data were immature. Conclusion: This study suggests a correlation between KRAS status and response to pembrolizumab.
Keyphrases
- wild type
- free survival
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- small cell lung cancer
- prognostic factors
- peritoneal dialysis
- advanced non small cell lung cancer
- radiation therapy
- gene expression
- drug delivery
- locally advanced
- dna methylation
- machine learning
- artificial intelligence
- deep learning
- patient reported
- big data
- rectal cancer
- data analysis
- electronic health record
- combination therapy
- study protocol